CVKD / Cadrenal Therapeutics, Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 28, 2026 Cadrenal Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 28, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fi

CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE

Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (the “Agreement”) is dated as of June 3, 2026, and entered into by and between Cadrenal Therapeutics, Inc., a Delaware corporation (together with each and every of its predecessors, successors (by merger or otherwise), partners, affiliates, joint venture partners, divisions

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2026 Cadrenal Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTIC

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 reg

Exhibit 99.1 Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT) PONTE VEDRA, Fla., May 7, 2026 - Cadrenal Therapeutics, Inc. (Nasda

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT

Exhibit 99.1 Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2026 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

1,180,003 Shares of Common Stock

Filed pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-295200 1,180,003 Shares of Common Stock This prospectus relates to the resale from time to time of up to an aggregate of 1,180,003 shares of common stock, par value $0.001 per share (the “Common Stock”), of Cadrenal Therapeutics, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholders”), including th

April 27, 2026

April 27, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

LETTER

April 27, 2026 Quang Pham Chairman and Chief Executive Officer Cadrenal Therapeutics, Inc.

As filed with the Securities and Exchange Commission on April 20, 2026

As filed with the Securities and Exchange Commission on April 20, 2026 Registration Statement No.

CALCULATION OF FILING FEE TABLES Cadrenal Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Cadrenal Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common St

Cadrenal Therapeutics, Inc.

Exhibit 10.1 Cadrenal Therapeutics, Inc. March 31, 2026 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Cadrenal Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Cadrenal Therapeutics, Inc.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Cadrenal Therapeutics, Inc. 590,001 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-283226 PROSPECTUS SUPPLEMENT NO. 1 (to the prospectus dated November 22, 2024) Cadrenal Therapeutics, Inc. 590,001 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in the Registration Statement on Form S-3, declared effective as of November 22, 2024 (as supplemented or amended from time

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2026 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

SERIES [B-1][B-2] COMMON STOCK PURCHASE WARRANT Cadrenal Therapeutics, Inc.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2026 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-

Exhibit 99.1 Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., March 31,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Exhibit 99.1 Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes PONTE VEDRA, FL, March 12, 2026 – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific findings demonstrating the pot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 12, 2026 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 12, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a backgroun

Exhibit 99.1 Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PON

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2026 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2026 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

428,227 Shares of Common Stock

Filed pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-292444 428,227 Shares of Common Stock This prospectus relates to the resale from time to time of up to an aggregate of 428,227 shares of common stock, par value $0.001 per share (the “Common Stock”), of Cadrenal Therapeutics, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholders”), including their

Filing Fee Table

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Cadrenal Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common St

As filed with the Securities and Exchange Commission on December 23, 2025

As filed with the Securities and Exchange Commission on December 23, 2025 Registration Statement No.

Up to $1,770,028 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT NO. 5 (To prospectus dated March 20, 2024) Up to $1,770,028 Shares of Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated March 20, 2024 (the “Base Prospectus”), filed with the Securities and Exchange Commission (the “SEC”) as part of our registration statement on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

207,374 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT (To Prospectus dated March 20, 2024) 207,374 Shares of Common Stock We are offering 207,374 shares of our common stock, par value $0.001 per share (the “Common Stock”) to certain institutional and accredited investors in a registered direct offering. In a concurrent private placement, we are also selling to such inv

COMMON STOCK PURCHASE WARRANT Cadrenal Therapeutics, Inc.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Cadrenal Therapeutics, Inc.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 15, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 15, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

The date of this prospectus supplement is December 15, 2025.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT No. 4 (To prospectus dated March 20, 2024) This prospectus supplement amends and supplements the information in the prospectus, dated March 20, 2024 (the “Base Prospectus”), filed with the Securities and Exchange Commission (the “SEC”) as part of our registration statement on Form S-3 (File No. 333-277835), which wa

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 15, 2025, between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.2 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated Exclusive License Agreement (“Agreement”) is entered into as of the 1st day of May, 2020 (“Effective Date”), by and between EASTERN VIRGINIA MEDICAL SCHOOL (“EVMS”) located at P.O. Box 1980 Norfolk, VA 23501-1980, U.S.A., and Veralox Therapeutics, Inc. 4539 Metropolitan Court, Frederick, MD 21704 (“LICENSEE”),

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Exhibit 99.1 FOR IMMEDIATE RELEASE Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) ● Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT ● It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it

FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “First Amendment”) is entered into effective as of December 9, 2025 (the “First Amendment Effective Date”), by and between OLD DOMINION UNIVERSITY, as successor in interest to EASTERN VIRGINIA MEDICAL SCHOOL (“EVMS”) at P.O. Box 1980, Norfol

Bridging Important Gaps in Anticoagulation Management for High - Risk Patients December 2025 Corporate Presentation NASDAQ: CVKD 2 Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we o

Exhibit 99.2 Bridging Important Gaps in Anticoagulation Management for High - Risk Patients December 2025 Corporate Presentation NASDAQ: CVKD 2 Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing . We base these forward - looking statements on our expe

ASSET PURCHASE AGREEMENT

Exhibit 10.1 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of December 10, 2025 (the “Execution Date”) by and between Cadrenal Therapeutics, Inc., a Delaware corporation (“Purchaser”), and VERALOX THERAPEUTICS Inc., a Delaware corporation (“Seller”). Purchaser and Seller are referred to in this Agreement individually as a “Party” and together as the “Parties.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 10, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 10, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Exhibit 99.1 Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors PONTE VEDRA, Fla., December 1, 2025 – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Gold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 24, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 24, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 18, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

Up to $3,438,062 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated March 20, 2024) Up to $3,438,062 Shares of Common Stock We have entered into an At the Market Offering Agreement, dated March 11, 2024 (the “sales agreement”), with H.C. Wainwright & Co., LLC (“Wainwright” or the “sales agent”) relating to the sale of shares of our common stock, par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2025 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PONTE VEDRA, Fla., November 10, 2025 – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, an

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 1693 23634.28 2046854 10/09/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 1693 05/17/2022 N/A N 10b5-1 Sales for MATTHEW S

144

144 0001405290 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X. Pham Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 1800 25227.76 2046854 10/09/2025 NASDAQ Common 01/25/2022 Founders Shares Issuer N 1800 01/25/2022 N/A N Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 107 1517.26 2046854 10/06/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 107 05/17/2022 N/A N 10b5-1 Sales for MATTHEW SZOT

144

144 0001405290 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X. Pham Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 500 7066 2046854 10/02/2025 NASDAQ Common 01/25/2022 Founders Shares Issuer N 500 01/25/2022 N/A N Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082

144

144 0001405290 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X. Pham Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 881 12343.19 2046854 10/01/2025 NASDAQ Common 01/25/2022 Founders Shares Issuer N 881 01/25/2022 N/A N Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 1700 23511.00 2046854 10/01/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 1700 05/17/2022 N/A N 10b5-1 Sales for MATTHEW S

144/A

144/A 0001628280-25-042842 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal Theraputics INC 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X.

144

144 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal TheraputicsINC 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X.

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 100 1403.00 2046854 09/29/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 100 05/17/2022 N/A N 10b5-1 Sales for MATTHEW SZOT

144

144 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal TheraputicsINC 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang X.

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 10900 150202.00 2046854 09/25/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 10900 05/17/2022 N/A N 10b5-1 Sales for MATTHE

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 1500 20520.00 2046854 09/24/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 1500 05/17/2022 N/A N 10b5-1 Sales for MATTHEW S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 24, 2025 Cadrenal Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 24, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commiss

144

144 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal TheraputicsINC 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA BEACH FL 32082 904-300-0701 Quang Pham Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 2581 36108 2046854 09/24/2025 NASDAQ Common 01/25/2022 Founders Shares Issuer N 2581 01/25/2022 N A N Quang Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082 Common 08/27/2025 3836 53455.

2

Exhibit 99.1 FOR IMMEDIATE RELEASE Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors ● Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings ● Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2025 Cadrenal Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 12, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commiss

ASSET PURCHASE AGREEMENT

Exhibit 10.1 CONFIDENTIAL ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of September 12, 2025 (the “Execution Date”) by and between Cadrenal Therapeutics, Inc., a Delaware corporation (“Purchaser”), and EXITHERA PHARMACEUTICALS Inc., a Delaware corporation (“Seller”). Purchaser and Seller are referred to in this Agreement individually as a “Party” and togethe

1 Bridging Critical Gaps in Anticoagulation Therapeutics Cadrenal Therapeutics, Inc. Nasdaq: CVKD September 2025 Confidential 2 Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or o

Exhibit 99.2 1 Bridging Critical Gaps in Anticoagulation Therapeutics Cadrenal Therapeutics, Inc. Nasdaq: CVKD September 2025 Confidential 2 Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing . We base these forward - looking statements on our expecta

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 9043000701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 400 5572.00 2046854 08/28/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 400 05/17/2022 N/A N 10b5-1 Sales for MATTHEW SZOT

144

144 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal Therapeutics, Inc. 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701 Pham Quang X Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 1193 16540.64 2046854 08/28/2025 NASDAQ Common 01/25/2022 Founders Shares Company N 1193 01/25/2022 N/A N Quang Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082 Com

144

144 0001401385 XXXXXXXX LIVE 0001937993 CADRENAL THERAPEUTICS, INC. 001-41596 822 A1A North, Suite 306 Ponte Vedra FL 32082 904-300-0701 MATTHEW SZOT Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 1600 22000.00 2046854 08/27/2025 NASDAQ Common 05/17/2022 Founders Shares Issuer N 1600 05/17/2022 N/A Y 08/27/2025 05/09/2025 /s

144/A

144/A 0002007317-25-000971 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal Therapeutics, Inc.

144

144 0001405290 XXXXXXXX LIVE 0001937993 Cadrenal Therapeutics, Inc. 001-41596 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701 Pham Quang X Officer Common Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082 30600 428094.00 2046854 08/27/2025 NASQ Common 01/25/2022 Private Placement Company N 30600 01/25/2022 Private Placement Y 08/27/2025 05/09/2025 Quang Pham

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 11, 2025 Cadrenal Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 11, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin can potent

Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin can potentially address critical treatment gaps in patients with ESKD Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2025 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, includ

Exhibit 99.1 FOR IMMEDIATE RELEASE Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial Addresses a cr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

FORM ARS

2024 Annual Report NASDAQ: CVKDUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2025 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 15, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 Cadrenal Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fil

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update Leadership appointment strengthens strategic and development capabilities. FDA Type D Meeting provides additional guidance for advancing the clinical dev

Exhibit 99.1 Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update Leadership appointment strengthens strategic and development capabilities. FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation options PONTE VEDRA, Fl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2025 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Up to $2,169,272 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus dated March 20, 2024) Up to $2,169,272 Shares of Common Stock We have entered into an At the Market Offering Agreement, dated March 11, 2024 (the “sales agreement”), with H.C. Wainwright & Co., LLC (“Wainwright” or the “sales agent”) relating to the sale of shares of our common stock, par value

Amended and Restated Insider Trading Policy

Exhibit 19.1 CADRENAL THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY Effective as of March 13, 2025 This Amended and Restated Insider Trading Policy (the “Policy”) provides the standards of Cadrenal Therapeutics, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly traded companies while in possession of confidential in

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin Recent Collaboration Agreement with Abbott Global Enterprises Limited (“Abbott”) in support of Phase 3 randomized, mult

Exhibit 99.1 Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin Recent Collaboration Agreement with Abbott Global Enterprises Limited (“Abbott”) in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2025 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Exhibit 99.1 Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD ● Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla., March 4, 2025 - Cadrenal Therapeutics, Inc. (Nasdaq

Collaboration Agreement between Abbott Global Enterprises Limited and Cadrenal Therapeutics, Inc.

Exhibit 10.1 COLLABORATION AGREEMENT This Collaboration Agreement (“Agreement”) is effective as of February 27, 2025 (“Effective Date”), by and between Abbott Global Enterprises Limited (“Abbott”) and Cadrenal Therapeutics, Inc. (“Cadrenal”). WHEREAS, Cadrenal is sponsoring a Phase 3 randomized, warfarin-controlled, multicenter study named TECarfarin Anticoagulation and Hemocompatibility with Left

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 3, 2025 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 3, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

Employment Agreement between Cadrenal Therapeutics, Inc. and James J. Ferguson III, effective February 5, 2025

Exhibit 10.1 Execution Copy EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into effective as of February 5, 2025 (the “Effective Date”) by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and James J. Ferguson III (“Executive”). Together, Executive and the Company are sometimes referred to as the “Parties.” Capitalized terms not otherwis

Severance and Release Letter Agreement, dated February 7, 2025, between Cadrenal Therapeutics, Inc. and Douglas Losordo

Exhibit 10.2 PRIVATE AND CONFIDENTIAL BY Email [email protected] Douglas Losordo 99 Catherine Road Scarsdale, NY 10583 February 4, 2025 Re: Confidential Severance and Release Letter Agreement Dear Douglas, This letter outlines the terms related to your separation from employment with Cadrenal Therapeutics, Inc. (the “Company”), which includes its affiliates and related companies or entities, dire

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Exhibit 99.1 Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin ● James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer ● Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 4, 2025 Cadrenal Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 4, 2025 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CADRENAL THERAPEUTICS, INC.

As filed with the Securities and Exchange Commission on February 3, 2025

As filed with the Securities and Exchange Commission on February 3, 2025 Registration No.

Annex A Transactions in the Shares of Common Stock by the Reporting Person Within the Last Sixty Days

EX-99.1 2 ea022913001ex99-1cardenal.htm ANNEX A Exhibit 99.1 Annex A Transactions in the Shares of Common Stock by the Reporting Person Within the Last Sixty Days Vesting of Stock Options During the last 60 days, a stock option to purchase 2,500 shares of the Issuer’s Common Stock previously granted under the Issuer’s equity plans vested. The Reporting Person currently has the following outstandin

JOINT FILING AGREEMENT

EX-2 3 ea022913001ex-2cardenal.htm JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT JOINT FILING AGREEMENT, dated as of January 29, 2025, among Quang Pham and The PVBQ Living Trust (collectively, the “Reporting Persons”). WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties hereto desire to satisfy any filing obligatio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CADRENAL THERAPEUTICS, INC.

As filed with the Securities and Exchange Commission on December 23, 2024

As filed with the Securities and Exchange Commission on December 23, 2024 Registration No.

Up to $2,512,330 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT (To Prospectus dated March 20, 2024) Up to $2,512,330 Shares of Common Stock We have entered into an At the Market Offering Agreement, dated March 11, 2024 (the “sales agreement”), with H.C. Wainwright & Co., LLC (“Wainwright” or the “sales agent”) relating to the sale of shares of our common stock, par value $0.001

590,001 Shares Of Common Stock

Filed pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-283226 590,001 Shares Of Common Stock This prospectus relates to the resale from time to time of up to an aggregate of 590,001 shares of common stock, par value $0.001 per share (the “common stock”), of Cadrenal Therapeutics, Inc. by the Selling Stockholders identified in this prospectus (the “Selling Stockholders”), including their

November 21, 2024

November 21, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

LETTER

November 20, 2024 Quang Pham Chief Executive Officer Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, FL 32082 Re: Cadrenal Therapeutics, Inc. Registration Statement on Form S-3 Filed November 14, 2024 File No. 333-283226 Dear Quang Pham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding req

As filed with the Securities and Exchange Commission on November 14, 2024.

As filed with the Securities and Exchange Commission on November 14, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CADRENAL THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 88-0860746 (State or other jurisdiction of incorporation or

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cadrenal Therapeutics, Inc.

CVKD / Cadrenal Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-cvkd093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cadrenal Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 127636207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 Cadrenal Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPE

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Exhibit 99.1 CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE PONTE VEDRA, Fla., Nov. 7, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the “Company” or “Cadrenal”), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with implanted cardiac devices or rare cardiovascular

Form of Placement Agent Warrant

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Cadrenal Therapeutics, Inc. 395,167 Shares of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-273384 PROSPECTUS SUPPLEMENT NO. 1 (to the prospectus dated April 2, 2024) Cadrenal Therapeutics, Inc. 395,167 Shares of Common Stock This prospectus supplement updates, amends and supplements the prospectus contained in our Post Effective Amendment No. 1 to the Registration Statement on Form S-1 on Form S-3, declared effective as of April 2, 2

Form of New Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Warrant Inducement Agreement

Exhibit 10.1 Cadrenal Therapeutics, Inc. November 1, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Cadrenal Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 p

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Exhibit 99.1 Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds PONTE VEDRA, Fla., November 1, 2024 /PRNewswire/ - Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 Cadrenal Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 24, 2024 Cadrenal Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 24, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Exhibit 99.1 Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility PONTE VEDRA, Fla., October 24, 2024 - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the “Company” or “Cadrenal”), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare

CVKD / Cadrenal Therapeutics, Inc. / Havlickova 648 a.s. - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Cadrenal Therapeutics, Inc. NASDAQ: CVKD September 2024 2 Caution Concerning Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or our representatives may make forward - looking state

Exhibit 99.1 Cadrenal Therapeutics, Inc. NASDAQ: CVKD September 2024 2 Caution Concerning Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing . We base these forward - looking statements on our expectations and projections about future events, which we

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 25, 2024 Cadrenal Thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 25, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2024 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 5, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference as Exhibit 3.1 to the Current Report on Form 8-K filed on August 20, 2024)

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CADRENAL THERAPEUTICS, INC. Cadrenal Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Cadrenal Therapeutics, Inc. 2. The Board of Directors of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 19, 2024 Cadrenal Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 19, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2024 Cadrenal Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 16, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CADRENAL THERAPEUTICS, INC. Cadrenal Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Cadrenal Therapeutics, Inc. 2. The Board of Directors of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update PONTE VEDRA, Fla., Aug. 7, 2024 /PRNewswire/ - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2024 Cadrenal Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Exhibit 99.1 Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2024 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on July 31, 2024)

EXHIBIT 10.1 AMENDMENT TO THE CADRENAL THERAPEUTICS, INC. 2022 SUCCESSOR EQUITY INCENTIVE PLAN Dated: July 29, 2024 WHEREAS, the Board of Directors (the “Board”) of Cadrenal Therapeutics, Inc. (the “Company”) heretofore established the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (the “Plan”); and WHEREAS, the Board desires to amend the Plan to increase the maximum number of sh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

ANNUAL REPORT

ANNUAL REPORT NASDAQ: CVKDDEAR SHAREHOLDERS In 2023, Cadrenal embarked on our exciting journey as a publicly traded company.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‌ For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2024 Cadrenal Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 9, 2023 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 9, 2023 Cadrenal Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (Former name or former address, if changed since last report) Delaware 001-41596 88-08

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts FDA designation provides potentially s

Exhibit 99.1 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla., April 9, 2024 /PR

As filed with the Securities and Exchange Commission on April 1, 2024

As filed with the Securities and Exchange Commission on April 1, 2024 Registration Statement No 333-273384 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

March 18, 2023

March 18, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

LETTER

United States securities and exchange commission logo March 15, 2024 Quang Pham President, Chief Executive Officer and Director Cadrenal Therapeutics, Inc.

Calculation of Filing Fees Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) CADRENAL THERAPEUTICS, INC.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CADRENAL THERAPEUTICS, INC.

At The Market Offering Agreement, dated March 11, 2024, by and between Cadrenal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to exhibit 1.1 to the Current Report on Form 8-K filed on March 11, 2024)

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT March 11, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Cadrenal Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in

Form of Indenture

Exhibit 4.3 CADRENAL THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec

As filed with the Securities and Exchange Commission on March 12, 2024

As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.

As filed with the Securities and Exchange Commission on March 12, 2024

As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 11, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries None

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 11, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Clawback Policy

Exhibit 97.1 CADRENAL THERAPEUTICS, INC. Clawback Policy The Board of Directors (the “Board”) of Cadrenal Therapeutics, Inc.(the “Company”) has determined that it is in the best interests of the Company to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy is designe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC

Insider Trading Policy

Exhibit 19.1 CADRENAL THERAPEUTICS, INC. INSIDER TRADING POLICY Effective as of January 19, 2023 This Insider Trading Policy provides the standards of Cadrenal Therapeutics, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly traded companies while in possession of confidential information. This policy is divided into two parts: the f

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update PONTE VEDRA, Fla., March 11, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditio

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 5, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 6,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 6, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of inco

CVKD / Cadrenal Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-cvkd123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cadrenal Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 127636108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t

CVKD / Cadrenal Therapeutics, Inc. / MURPHY JOHN RAYMOND - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea193651-13ga1murphycadren.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Cadrenal Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 127636 108 (CUSIP Number) John Raymond Murphy c/o Cadrenal The

JOINT FILING AGREEMENT

EX-99.1 2 ea193366ex99-1cadrenal.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT JOINT FILING AGREEMENT, dated as of February 12, 2024, among Quang Pham and The PVBQ Living Trust (collectively, the “Reporting Persons”). WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties hereto desire to satisfy any filing obligatio

Employment Agreement, effective as of February 8, 2024, between Cadrenal Therapeutics, Inc. and Jeffrey Cole (Incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K filed on February 12, 2024)

Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of February 8, 2024 by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Jeffrey S. Cole (“Executive”). Together, Executive and the Company are sometimes referred to as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings set forth in Secti

Offer Letter dated, February 6, 2024, between Cadrenal Therapeutics, Inc. and Jeffrey Cole (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K filed on February 12, 2024)

Exhibit 10.1 February 6, 2024 Jeffrey S. Cole Via email: [email protected] Dear Jeff, We are pleased to offer you the position of Chief Operating Officer (“COO”) (“Executive”) of Cadrenal Therapeutics, Inc. In the capacity of COO, the Executive will render such business and professional services in the performance of his duties, consistent with the Executive’s position within the Company. Sp

CVKD / Cadrenal Therapeutics, Inc. / Pham Quang X - SCHEDULE 13G Passive Investment

SC 13G 1 ea193366-13gphamcadrenal.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cadrenal Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 127636 108 (CUSIP Number) Quang Pham c/o Cadrenal Therapeutics, Inc. 822 A1A North, Sui

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Exhibit 99.1 Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 6, 2024 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEU

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update PONTE VEDRA, Fla., November 9, 2023 - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (“Cadrenal Therapeutics” or the “Company”) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 20, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 6, 2023 Cadrenal Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 6, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

FORM ARS

Cadrenal Therapeutics, Inc. | Nasdaq: CVKD 2022 Annual Report to ShareholdersUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti

1 CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD August 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time, we or our representatives ma

Exhibit 99.1 1 CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD August 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing. We base these forward - looking statements on our expectations and projections

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 17, 2023 Cadrenal Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 17, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events, Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 15, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

Cadrenal Therapeutics, Inc.

Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3) (To Prospectus dated July 28, 2023) Registration No. 333-273384 8,850,001 Shares Common Stock Cadrenal Therapeutics, Inc. This prospectus supplement No. 1 amends and supplements the Cadrenal Therapeutics, Inc. prospectus dated July 28, 2023, which was filed with the Securities and Exchange Commission on August 1, 2023 (the “Prospectus”),

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS,

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update PONTE VEDRA, Fla., Aug. 10, 2023 /PRNewswire/ - Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical condi

The date of this prospectus is July 28, 2023 TABLE OF CONTENTS

Filed Pursuant to Rule 424(b)(3) PROSPECTUS Registration No. 333-273384 8,850,001 Shares Common Stock Cadrenal Therapeutics, Inc. This prospectus relates to the resale from time to time of up to 8,850,001 shares of Common Stock, par value $0.001 per share (the “Common Stock”), of Cadrenal Therapeutics, Inc. by the selling stockholders identified in this prospectus (the “Selling Stockholders”), inc

LETTER

United States securities and exchange commission logo July 26, 2023 Quang Pham President, Chief Executive Officer and Director Cadrenal Therapeutics, Inc.

July 26, 2023

July 26, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

As filed with the Securities and Exchange Commission on July 24, 2023

As filed with the Securities and Exchange Commission on July 24, 2023 Registration Statement No 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Calculation of Filing Fees Table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Cadrenal Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 23, 2023 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 23, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Exhibit 99.1 Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors PONTE VEDRA, Fla., July 24, 2023 - Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of R

Form of Registration Rights Agreement (Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K (001-41596), as filed with the SEC on July 14, 2023)

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of , 2023, between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Ag

Form of Placement Agent Warrant (Incorporated by reference as Exhibit 4.3 to the Current Report on Form 8-K 001-41596), as filed with the SEC on July 14, 2023)

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement (Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (001-41596), as filed with the SEC on July 14, 2023)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 12, 2023, between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condit

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Exhibit 99.2 Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules PONTE VEDRA, Fla., July 14, 2023 /PRNewswire/ - Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical condit

Form of Common Stock Warrant (Incorporated herein by reference to Exhibit 4.2 of the Registrant’s Current Report on Form 8-K (001-41596), as filed with the SEC on July 14, 2023)

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Exhibit 99.1 Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules PONTE VEDRA, Fla., July 12, 2023 /PRNewswire/ - Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 12, 2023 Cadrenal Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 12, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission F

Form of Lock-Up Agreement

Exhibit 10.3 LOCK-UP AGREEMENT July 12, 2023 Re: Securities Purchase Agreement, dated as of July 12, 2023 (the “Purchase Agreement”), between Cadrenal Therapeutics, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have

Form of Pre-Funded Warrant (Incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K 001-41596), as filed with the SEC on July 14, 2023)

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Amendment No. 1 to Employment Agreement by and between Cadrenal Therapeutics, Inc. and Matthew Szot, dated May 25, 2023 (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on May 26, 2023)

Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment”), effective as of June 1, 2023 (the “Effective Date”), by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Matthew K. Szot (the “Executive”). Together, the Company and the Executive are sometimes referred to as the “Parties”. WHEREAS, the Company and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2023 Cadrenal Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fi

Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update

Exhibit 99.1 Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update PONTE VEDRA, Florida – May 10, 2023 – Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today’s filing of its Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2023 Cadrenal Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2023 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-41596 88-0860746 (State or other jurisdiction of incorporation) (Commission Fi

Exhibit 4.11

Exhibit 4.11 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Cadrenal Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which is our common stock, par value $0.001 per share (the “common stock”). Gene

Subsidiaries of Registrant (Incorporated by reference as Exhibit 21.1 to the Annual Report on Form 10-K (001-41596) filed with the SEC on March 30, 2023)

Exhibit 21.1 List of Subsidiaries None

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41596 CADRENAL THERAPEUTICS, INC

CVKD / Cadrenal Therapeutics Inc / MURPHY JOHN RAYMOND - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cadrenal Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 127636 108 (CUSIP Number) John Raymond Murphy c/o Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 (904) 30

1 CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD March 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time, we or our representatives may

Exhibit 99.1 1 CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD March 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing. We base these forward - looking statements on our expectations and projections a

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 27, 2023 Cadrenal Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (Former name or former address, if changed since last report) Delaware 001-41596 88-0

Employment Agreement with Matthew Szot (Incorporated by reference as Exhibit 10.3 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)

Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of January 24, 2023 by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Matthew K. Szot (“Executive”). Together, Executive and the Company are sometimes referred to as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings set forth in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 19, 2023 Cadrenal Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 19, 2023 Cadrenal Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (Former name or former address, if changed since last report) Delaware 001-41596 88

Amendment to Asset Purchase Agreement, dated as of August 18, 2022, between Cadrenal Therapeutics, Inc. and HESP LLC (Incorporated by reference as Exhibit 10.2 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)

Exhibit 10.2 AMENDMENT TO ASSET PURCHASE AGREEMENT This Amendment to the Asset Purchase Agreement (“Amendment”), dated August 18, 2022, is entered into by and between HESP LLC, a Delaware limited liability company (“Seller”) and Cadrenal Therapeutics, Inc., a Delaware corporation (“Purchaser”). WHEREAS, Seller and Purchaser are parties to that certain Asset Purchase Agreement, dated April 1, 2022

Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)

Exhibit 99.1 Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) PONTE VEDRA, Fla., Jan. 20, 2023 /PRNewswire/ - Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today the pricing of its initial public offering of 1,400,000 shares of common stock at a pu

Form of Indemnification Agreement (Incorporated by reference as Exhibit 10.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)

Exhibit 10.1 CADRENAL THERAPEUTICS, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of , by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, the Company and Indemnitee recognize the substantial increase in corporate litigation in general, subjecting officers and directors to expensive li

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

EX-99.2 9 ea172140ex99-2cadrenal.htm PRESS RELEASE ANNOUNCING FAST TRACK DESIGNATION FOR TECARFARIN, DATED JANUARY 23, 2023 Exhibit 99.2 Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation PONTE VEDRA, Fla., Jan. 23, 2023 /PRNewswire/ - Ca

Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering

Exhibit 99.3 Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares

Employment Agreement with Douglas Losordo (Incorporated by reference as Exhibit 10.4 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)

EX-10.4 7 ea172140ex10-4cadrenal.htm EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 24, 2023, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND DOUGLAS LOSORDO Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of September 21, 2022 by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) and Douglas Losordo (“Executive”). Togeth

Underwriting Agreement, dated January 19, 2023, by and between Cadrenal Therapeutics, Inc. and Boustead Securities, LLC, as representative of the underwriters (Incorporated by reference as Exhibit 1.1 to the Current Report on Form 8-K (001-41596), as filed with the SEC on January 25, 2023)

EX-1.1 2 ea172140ex1-1cadrenal.htm UNDERWRITING AGREEMENT, DATED JANUARY 19, 2023, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND BOUSTEAD SECURITIES, LLC Exhibit 1.1 UNDERWRITING AGREEMENT January 19, 2023 Boustead Securities, LLC 6 Venture, Suite 265 Irvine, CA 92618 As Representative of the several Underwriters named on Schedule 1 attached hereto Ladies and Gentlemen: The undersigned, Cadrenal

Representative’s Warrant issued to Boustead Securities, LLC dated January 19, 2023 (Incorporated by reference as Exhibit 4.1 to the Current Report on Form 8-K (001-41596) filed with the SEC on January 25, 2023)

Exhibit 4.1 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING JANUARY 19, 2023 (THE “EF

As filed with the Securities and Exchange Commission on January 23, 2022

As filed with the Securities and Exchange Commission on January 23, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics, Inc. 1,400,000 Shares Common Stock

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No: 333-267562 Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. 1,704,783 shares of common stock

PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No: 333-267562 Cadrenal Therapeutics, Inc.

CERT

The Nasdaq Stock Market LLC, 805 King Farm Blvd., Rockville, MD 20850 Eun Ah Choi Senior Vice President U.S. Listing Qualifications & Market Surveillance January 20, 2023 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on January 17, 2023, The Nasdaq Stock Market LLC (the "Exc

REDACTED EXHIBIT

January 20, 2023 Quang Pham Chief Executive Officer Cadrenal Therapeutics, Inc. 822 A1A North, Suite 320 Ponte Vedra, FL 32082 Re: Cadrenal Therapeutics, Inc. Amendment. No. 6 to Registration Statement on Form S-1 Exhibit No. 10.13 Filed January 17, 2023 File No. 333-267562 Dear Quang Pham: We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements a

As filed with the Securities and Exchange Commission on January 17, 2023.

As filed with the Securities and Exchange Commission on January 17, 2023. Registration No. 333-267562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 88-0860746 (State or other jurisdiction of in

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CADRENAL THERAPEUTICS, INC.

Boustead Securities LLC 6 Venture #395 Irvine, CA 92618 January 17, 2023

Boustead Securities LLC 6 Venture #395 Irvine, CA 92618 January 17, 2023 Securities and Exchange Commission 100 F Street, N.

January 17, 2023

January 17, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

As filed with the Securities and Exchange Commission on December 27, 2022.

As filed with the Securities and Exchange Commission on December 27, 2022. Registration No. 333-267562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 88-0860746 (State or other jurisdiction of i

Form of Underwriting Agreement by and between Cadrenal Therapeutics, Inc. and Boustead Securities, LLC, as representative of the underwriters

Exhibit 1.1 UNDERWRITING AGREEMENT , 2022 Boustead Securities, LLC 6 Venture, Suite 265 Irvine, CA 92618 As Representative of the several Underwriters named on Schedule 1 attached hereto Ladies and Gentlemen: The undersigned, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with Boustead Securities, LLC (hereinafter referred to a

As filed with the Securities and Exchange Commission on December 8, 2022.

S-1/A 1 fs12022a4cadrenal.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 8, 2022. Registration No. 333-267562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delawa

LETTER

United States securities and exchange commission logo December 8, 2022 Quang Pham Chief Executive Officer Cadrenal Therapeutics, Inc.

December 8, 2022

Phone: (212) 885-5358 Fax: (917) 332-3824 Email: [email protected] December 8, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Cadrenal Therapeutics, Inc. Amendment No. 3 to Registration Statement on Form S-1 Submitted on December 6, 2022 File No. 333-267562 Dear Mr. Hag

Form of Amendment to Convertible Promissory Note (Incorporated by reference as Exhibit 4.10 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)

EX-4.10 8 fs12022a3ex4-10cadrenal.htm FORM OF AMENDMENT TO CONVERTIBLE PROMISSORY NOTE Exhibit 4.10 FORM OF AMENDMENT TO CONVERTIBLE PROMISSORY NOTE THIS AMENDMENT TO CONVERTIBLE PROMISSORY NOTE (this “Agreement”), dated December , 2022, is made by and between Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), [ ] (the “Holder”). WHEREAS, Holder executed and delivered a Convertib

Form of November Private Placement Promissory Note (Incorporated by reference as Exhibit 4.6 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)

Exhibit 4.6 Form of Note THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER

Form of Amended and Restated November Warrant (Incorporated by reference as Exhibit 4.7 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)

Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Amended and Restated Placement Agent Warrant from Private Placement (Incorporated by reference as Exhibit 4.8 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)

Exhibit 4.8 THESE WARRANTS AND ANY SHARES ACQUIRED UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. THESE WARRANTS AND SUCH SHARES AND ANY INTEREST OR PARTICIPATION HEREIN OR THEREIN MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT A

Amended and Restated Bylaws (Incorporated by reference as Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-267562) filed on December 6, 2022)

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CADRENAL THERAPEUTICS, INC. aMENDED AND RESTATED BYLAWS OF CADRENAL THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The address of the registered office of Cadrenal Therapeutics, Inc. (the ?corporation?) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) CADRENAL THERAPEUTICS, INC.

Form of Placement Agent Warrant from November Private Placement (Incorporated by reference as Exhibit 4.9 to the Registration Statement on Form S-1 (333-267562) filed on December 6, 2022)

Exhibit 4.9 THESE WARRANTS AND ANY SHARES ACQUIRED UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. THESE WARRANTS AND SUCH SHARES AND ANY INTEREST OR PARTICIPATION HEREIN OR THEREIN MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT A

Amended and Restated Certificate of Incorporation

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CADRENAL THERAPEUTICS INC. CADRENAL THERAPEUTICS INC., a corporation organized and existing under the laws of the State of Delaware, DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?Cadrenal Therapeutics Inc.?. The original certificate of incorporation was filed with the Secretary of State of the State of Delaware o

As filed with the Securities and Exchange Commission on December 6, 2022.

As filed with the Securities and Exchange Commission on December 6, 2022. Registration No. 333-267562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cadrenal Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 88-0860746 (State or other jurisdiction of in

Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan

Exhibit 10.16 CADRENAL THERAPEUTICS, INC. 2022 SUCCESSOR EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2022 APPROVED BY THE STOCKHOLDERS: , 2022 1. General. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Availa

October 17, 2022

CORRESP 1 filename1.htm Phone: (212) 885-5358 Fax: (917) 332-3824 Email: [email protected] October 17, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Cadrenal Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Submitted on October 11, 2022 File No.

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan

Exhibit 10.18 CADRENAL THERAPEUTICS, INC. RSU AWARD GRANT NOTICE (2022 SUCCESSOR EQUITY INCENTIVE PLAN) Cadrenal Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein